View ValuationCuratis Holding 향후 성장Future 기준 점검 1/6Curatis Holding의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Pharmaceuticals 이익 성장10.3%매출 성장률16.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트24 Nov 2025최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Sep 18Curatis Holding AG Announces FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 - Corticorelin on Track for Phase 3Curatis Holding AG received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary to solid tumor brain metastases. The Phase 3 will utilize an adaptive trial design consisting of a dose optimization lead-in and confirmatory segment. PTBE occurs in association with many primary and metastatic (secondary) brain tumors, often in connection with metastases caused by lung cancer, breast cancer, melanoma and colorectal cancer. PTBE results in impairment of brain function due to the accumulation of extracellular fluid around the tumor and can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status. Standard of care treatment for PTBE is the use of corticosteroids which frequently have serious side effects such as severe myopathy, impared glucose metabolism, muscle wasting, abnormal weight gain, oeoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. Additionally, corticosteroids can also counteract certain cancer therapies such as chemotherapy or emerging immunotherapies. In the US alone, more than 150,000 patients suffer from PTBE.공시 • May 23Curatis Holding AG Announces Executive ChangesCuratis Holding AG announced strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC). Kirsty Crame, MD, was educated at the University of Amsterdam as a Doctor of Medicine. She has more than 12 years of experience in clinical development, of which more than 10 years have been in the field of immuno-oncology in a variety of indications for rare and non-rare diseases. Kirsty was previously a member of the Executive Committee and Vice President of Clinical Strategy and Development at Medigene, a German biotech company specializing in the development of highly innovative, T-cell receptor-directed cancer therapies. Prior to that, she was Director of Clinical Development at Gadeta, a Dutch company specializing in the development of novel immunotherapies. Kirsty will support Curatis in the preparation and conduct of the pivotal Phase 3 study with C-PTBE-01 and also brings extensive experience in regulatory affairs. Timm Trenktrog, PhD, worked for Actelion Pharmaceuticals Ltd. in Switzerland for more than 19 years, most recently as Vice President and Head of Technical Operations on the Executive Board. As a leading pharmaceutical expert, he lectured for over 10 years at the ETH Zurich on quality, production and technical development. Timm will support Curatis in the area of technical development and manufacturing (CMC) for C-PTBE-01 to ensure smooth production and the highest quality of the active ingredient, dosage form and final product.공시 • Mar 11Curatis Announces Formation of Distinguished Advisory BoardCuratis Holding announced the formation of an Advisory Board comprised of four internationally recognized experts across multiple medical and scientific disciplines. The board brings together leaders in pediatric oncology, neurology, drug development, and biochemistry to guide Curatis's research initiatives and strategic direction. The Advisory Board includes: Stewart Goldman, MD – An internationally renowned pediatric oncologist who serves as Chair of the Department of Child Health at the University of Arizona College of Medicine - Phoenix and Senior Vice President of Research at Phoenix Children's. Dr. Goldman oversees more than 700 research studies and is an accomplished leader in brain tumor research with over 170 peer-reviewed publications. Previously, he spent 23 years at Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine. Prof. Dr. Andreas Gantenbein – Past-president of the Swiss Headache Society and a distinguished neurologist whose research focuses on clinical studies including medication overuse headache, menstrual migraine, and CGRP-antibodies. Prof. Gantenbein began his career as a clinical research fellow in the Headache Group at Queen Square, London, and has since published more than 100 articles in peer-reviewed journals. He currently runs a private practice in Bülach after serving as Chief Physician of Neurology at the rehabilitation center RehaClinic Bad Zurzach. Dr. Anthony Man, B.Med Sci, MB, BS, FRCP (UK) – A physician with over 35 years of experience in international clinical research and drug development across multiple therapeutic areas. Dr. Man has contributed to more than 30 successful new drug applications and has held senior management positions at pharmaceutical companies including Lederle, Roche, Ciba Geigy, and Novartis. He also served as Chief Development Officer and Chief Executive Officer of Basilea Pharmaceutica from 2000-2013. Prof. Dr. Arnim Pause, M.Sc., Ph.D. – A Professor of Biochemistry at McGill University'sGoodman Cancer Institute and the Department of Biochemistry in Montreal, Canada. Prof. Pause is also Senior Director of Research at Kreamedica Inc. and has authored over 90 high-impact peer-reviewed publications, book chapters, and patents. With experience in both academia and industry, his research expertise spans molecular medicine with a focus on cancer biology.공시 • Nov 14Curatis Holding AG to Apply for A Biologic License for C-PTBE-01 in the USACuratis Holding AG has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years.공시 • May 31Curatis Holding AG, Annual General Meeting, Jun 21, 2024Curatis Holding AG, Annual General Meeting, Jun 21, 2024, at 14:00 W. Europe Standard Time. Location: pratteln Switzerland공시 • Jan 29Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction.Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction on January 29, 2024. Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share (into one newly issued Kinarus Holding share, whereby the consideration consists of approx. 14x the number of outstanding Kinarus shares (the “Consideration Shares”). Kinarus Holding shall be renamed to Curatis Holding AG with a proposed change of ticker symbol to (“CURE”) and the domicile of the Company be moved to Liestal, Basel-Landschaft. All shareholders of Curatis shall contribute and exchange their Curatis Shares (as a contribution in kind in an ordinary capital increase of Kinarus Holding) into Consideration Shares in the context of this contemplated transaction. In addition to the Combination Transaction, Kinarus Holding and Curatis have placed an offer with the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to purchase selected assets (patents, products and precursor, intellectual property as well as data of Kinarus AG in Liquidation relating to their lead product candidate, KIN001) from the bankruptcy estate of Kinarus AG in Liquidation, a 100% subsidiary of Kinarus Holding. Concurrently, also subject to approval by the Extraordinary General Meeting of Kinarus Holding, the Company will reduce the nominal value of the New Kinarus Shares from CHF 44.80 post Reserve Share Split to CHF 0.10 with a swap of CHF 44.70 in nominal amount per New Kinarus Share from share capital into statutory capital reserves. As a result, the nominal value per New Kinarus Shares will be CHF0.10. The final details of the Reverse Share Split transaction are expected to be announced together with the invititation to the Extraordinary General Meeting of Kinarus Holding in February 2024. As a result of all these transactions, the currently outstanding share capital of Kinarus Holding will be aggregated in the ratio 4,480:1, leading to 292,450 New Kinarus Shares post Reverse Share Split. In the context of the closing of the Combination Transaction, 4,093,916 New Kinarus Shares will be issued and used to settle the Combination Transaction with a share exchange ratio 1:1 for Curatis shares. Post the implementation of the Transaction, Kinarus Holding is expected to have an issued share capital of CHF438,636.60, divided into 4,386,366 New Kinarus Holding shares with nominal value CHF0.10 each. In addition, Kinarus Holding will have a maximum of approx. 850,000 options outstanding to third parties to purchase New Kinarus Shares so that the maximum total amount of fully diluted number of New Kinarus Shares outstanding is approximately 5,250,000. In the context of the Combination Transaction, it is envisaged that an up to CHF 5.5 milllion financing transaction in the form of a Mandatory Exchangeable Loan Note issued by Curatis (the “Financing Round”) is implemented. The closing of the Transaction is subject to various conditions Approval by the courts of Basel-Stadt to revert bankruptcy for Kinarus Holding, Approval of all proposed resolutions to the Extraordinary General Meeting of Kinarus Holding, being scheduled for on or around end of February or early March 2024, Approval by the SIX Swiss Exchange of the listing of the newly issued shares of Kinarus Holding in the frame of the Transaction and Approval by the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to sell the assets, patents, IP and data relating to KIN001 in line with the submitted offer by Kinarus Holding and Curatis. The Transaction is expected to close in Q2 2024.이익 및 매출 성장 예측SWX:CURN - 애널리스트 향후 추정치 및 과거 재무 데이터 (CHF Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202861N/A3737112/31/202721N/A33112/31/202699N/A8282112/31/202511-1-3-1N/A9/30/202510-2-2-1N/A6/30/202510-2-1-1N/A3/31/20259-3-1-1N/A12/31/20247-4-1-1N/A9/30/20244-28-1-1N/A6/30/20242-51-1-1N/A3/31/20241-50-1-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CURN 의 예상 수익 증가율이 절약률(0.6%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: CURN 의 수익이 Swiss 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: CURN 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: CURN 의 수익(연간 16.4%)이 Swiss 시장(연간 4.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CURN 의 수익(연간 16.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CURN의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 20:23종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Curatis Holding AG는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bob PoolerValuationLAB AG
공시 • Sep 18Curatis Holding AG Announces FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 - Corticorelin on Track for Phase 3Curatis Holding AG received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary to solid tumor brain metastases. The Phase 3 will utilize an adaptive trial design consisting of a dose optimization lead-in and confirmatory segment. PTBE occurs in association with many primary and metastatic (secondary) brain tumors, often in connection with metastases caused by lung cancer, breast cancer, melanoma and colorectal cancer. PTBE results in impairment of brain function due to the accumulation of extracellular fluid around the tumor and can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status. Standard of care treatment for PTBE is the use of corticosteroids which frequently have serious side effects such as severe myopathy, impared glucose metabolism, muscle wasting, abnormal weight gain, oeoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. Additionally, corticosteroids can also counteract certain cancer therapies such as chemotherapy or emerging immunotherapies. In the US alone, more than 150,000 patients suffer from PTBE.
공시 • May 23Curatis Holding AG Announces Executive ChangesCuratis Holding AG announced strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC). Kirsty Crame, MD, was educated at the University of Amsterdam as a Doctor of Medicine. She has more than 12 years of experience in clinical development, of which more than 10 years have been in the field of immuno-oncology in a variety of indications for rare and non-rare diseases. Kirsty was previously a member of the Executive Committee and Vice President of Clinical Strategy and Development at Medigene, a German biotech company specializing in the development of highly innovative, T-cell receptor-directed cancer therapies. Prior to that, she was Director of Clinical Development at Gadeta, a Dutch company specializing in the development of novel immunotherapies. Kirsty will support Curatis in the preparation and conduct of the pivotal Phase 3 study with C-PTBE-01 and also brings extensive experience in regulatory affairs. Timm Trenktrog, PhD, worked for Actelion Pharmaceuticals Ltd. in Switzerland for more than 19 years, most recently as Vice President and Head of Technical Operations on the Executive Board. As a leading pharmaceutical expert, he lectured for over 10 years at the ETH Zurich on quality, production and technical development. Timm will support Curatis in the area of technical development and manufacturing (CMC) for C-PTBE-01 to ensure smooth production and the highest quality of the active ingredient, dosage form and final product.
공시 • Mar 11Curatis Announces Formation of Distinguished Advisory BoardCuratis Holding announced the formation of an Advisory Board comprised of four internationally recognized experts across multiple medical and scientific disciplines. The board brings together leaders in pediatric oncology, neurology, drug development, and biochemistry to guide Curatis's research initiatives and strategic direction. The Advisory Board includes: Stewart Goldman, MD – An internationally renowned pediatric oncologist who serves as Chair of the Department of Child Health at the University of Arizona College of Medicine - Phoenix and Senior Vice President of Research at Phoenix Children's. Dr. Goldman oversees more than 700 research studies and is an accomplished leader in brain tumor research with over 170 peer-reviewed publications. Previously, he spent 23 years at Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine. Prof. Dr. Andreas Gantenbein – Past-president of the Swiss Headache Society and a distinguished neurologist whose research focuses on clinical studies including medication overuse headache, menstrual migraine, and CGRP-antibodies. Prof. Gantenbein began his career as a clinical research fellow in the Headache Group at Queen Square, London, and has since published more than 100 articles in peer-reviewed journals. He currently runs a private practice in Bülach after serving as Chief Physician of Neurology at the rehabilitation center RehaClinic Bad Zurzach. Dr. Anthony Man, B.Med Sci, MB, BS, FRCP (UK) – A physician with over 35 years of experience in international clinical research and drug development across multiple therapeutic areas. Dr. Man has contributed to more than 30 successful new drug applications and has held senior management positions at pharmaceutical companies including Lederle, Roche, Ciba Geigy, and Novartis. He also served as Chief Development Officer and Chief Executive Officer of Basilea Pharmaceutica from 2000-2013. Prof. Dr. Arnim Pause, M.Sc., Ph.D. – A Professor of Biochemistry at McGill University'sGoodman Cancer Institute and the Department of Biochemistry in Montreal, Canada. Prof. Pause is also Senior Director of Research at Kreamedica Inc. and has authored over 90 high-impact peer-reviewed publications, book chapters, and patents. With experience in both academia and industry, his research expertise spans molecular medicine with a focus on cancer biology.
공시 • Nov 14Curatis Holding AG to Apply for A Biologic License for C-PTBE-01 in the USACuratis Holding AG has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years.
공시 • May 31Curatis Holding AG, Annual General Meeting, Jun 21, 2024Curatis Holding AG, Annual General Meeting, Jun 21, 2024, at 14:00 W. Europe Standard Time. Location: pratteln Switzerland
공시 • Jan 29Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction.Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG (SWX:KNRS) in a reverse merger transaction on January 29, 2024. Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share (into one newly issued Kinarus Holding share, whereby the consideration consists of approx. 14x the number of outstanding Kinarus shares (the “Consideration Shares”). Kinarus Holding shall be renamed to Curatis Holding AG with a proposed change of ticker symbol to (“CURE”) and the domicile of the Company be moved to Liestal, Basel-Landschaft. All shareholders of Curatis shall contribute and exchange their Curatis Shares (as a contribution in kind in an ordinary capital increase of Kinarus Holding) into Consideration Shares in the context of this contemplated transaction. In addition to the Combination Transaction, Kinarus Holding and Curatis have placed an offer with the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to purchase selected assets (patents, products and precursor, intellectual property as well as data of Kinarus AG in Liquidation relating to their lead product candidate, KIN001) from the bankruptcy estate of Kinarus AG in Liquidation, a 100% subsidiary of Kinarus Holding. Concurrently, also subject to approval by the Extraordinary General Meeting of Kinarus Holding, the Company will reduce the nominal value of the New Kinarus Shares from CHF 44.80 post Reserve Share Split to CHF 0.10 with a swap of CHF 44.70 in nominal amount per New Kinarus Share from share capital into statutory capital reserves. As a result, the nominal value per New Kinarus Shares will be CHF0.10. The final details of the Reverse Share Split transaction are expected to be announced together with the invititation to the Extraordinary General Meeting of Kinarus Holding in February 2024. As a result of all these transactions, the currently outstanding share capital of Kinarus Holding will be aggregated in the ratio 4,480:1, leading to 292,450 New Kinarus Shares post Reverse Share Split. In the context of the closing of the Combination Transaction, 4,093,916 New Kinarus Shares will be issued and used to settle the Combination Transaction with a share exchange ratio 1:1 for Curatis shares. Post the implementation of the Transaction, Kinarus Holding is expected to have an issued share capital of CHF438,636.60, divided into 4,386,366 New Kinarus Holding shares with nominal value CHF0.10 each. In addition, Kinarus Holding will have a maximum of approx. 850,000 options outstanding to third parties to purchase New Kinarus Shares so that the maximum total amount of fully diluted number of New Kinarus Shares outstanding is approximately 5,250,000. In the context of the Combination Transaction, it is envisaged that an up to CHF 5.5 milllion financing transaction in the form of a Mandatory Exchangeable Loan Note issued by Curatis (the “Financing Round”) is implemented. The closing of the Transaction is subject to various conditions Approval by the courts of Basel-Stadt to revert bankruptcy for Kinarus Holding, Approval of all proposed resolutions to the Extraordinary General Meeting of Kinarus Holding, being scheduled for on or around end of February or early March 2024, Approval by the SIX Swiss Exchange of the listing of the newly issued shares of Kinarus Holding in the frame of the Transaction and Approval by the bankruptcy administrator ("Konkursverwaltung") of Basel-Stadt to sell the assets, patents, IP and data relating to KIN001 in line with the submitted offer by Kinarus Holding and Curatis. The Transaction is expected to close in Q2 2024.